ArriVent BioPharma (AVBP) financial statements
Net income was -$166M.
The diluted share count rose 1697% over the period (dilution).
Income statement
Fiscal years, from ArriVent BioPharma's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Research and development | $65M | $79M | $153M |
| Selling, general and admin | $10M | $15M | $24M |
| Operating income | -$75M | -$94M | -$178M |
| Net income | -$69M | -$80M | -$166M |
| EPS (diluted) | -$32.38 | -$2.56 | -$4.32 |
| Diluted shares | 2M | 31M | 38M |
Balance sheet
Fiscal years, from ArriVent BioPharma's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $150M | $219M | $313M |
| Total current assets | $160M | $227M | $333M |
| Total assets | $163M | $275M | $333M |
| Total current liabilities | $12M | $17M | $26M |
| Total liabilities | $12M | $17M | $26M |
| Shareholders' equity | -$153M | $258M | $307M |
| Net debt | -$150M | -$74M | -$46M |
Cash flow
Fiscal years, from ArriVent BioPharma's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$56M | -$70M | -$161M |
| Stock-based compensation | $895,000 | $3M | $13M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AVBP.
Open AVBP in InvestinglyFrom ArriVent BioPharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.